Data presented at the 2023 Cambridge Health Tech Institute's 2nd Annual Neurodegeneration Targets Conference in Boston, MAIn preclinical testing, NC181 demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance and other important findings BELTSVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, including neuroinflammatory disease, today announced the presentation of preclinical data relating to NC181, a novel humanized antibody targeting ApoE4, for the treatment of Alzheimer’s disease (AD), at the 2nd Annual Neurodegeneration Targets, Drug Discovery for Progressive Central Nervous System Disorders conference.

2023年剑桥健康技术研究所在波士顿举行的第二届年度神经退行性病变目标会议（主要临床前试验，NC181）上提供的数据显示淀粉样蛋白清除，预防淀粉样蛋白沉积，斑块清除和其他重要发现BELTSVILLE，Md，2023年9月26日（GLOBE NEWSWIRE））-NextCure，Inc。（纳斯达克股票代码：NXTC），一家临床阶段生物制药公司致力于发现和开发用于治疗癌症和其他免疫相关疾病（包括神经炎症性疾病）的新型一流免疫药物，今天宣布提供与NC181相关的临床前数据，NC181是一种靶向ApoE4的新型人源化抗体，用于治疗阿尔茨海默病（AD），在第二届年度神经变性目标，进展性中枢神经系统疾病药物发现会议上。

Published research has shown that different forms of the apolipoprotein E (APOE) gene affect the risk of developing AD in distinct ways, with the APOE4 allele most highly associated with and linked to increased risk. The ApoE4 isoform increases ab amyloid plaque formation, promotes Tau spreading, disrupts the blood brain barrier (BBB), promotes neurovasculature leakage, and increases microglia-mediated inflammation, which has been shown to lead to cognitive decline.

已发表的研究表明，不同形式的载脂蛋白E（APOE）基因以不同的方式影响发生AD的风险，APOE4等位基因与风险增加高度相关并与之相关。ApoE4亚型增加ab淀粉样斑块形成，促进Tau扩散，破坏血脑屏障（BBB），促进神经血管渗漏，并增加小胶质细胞介导的炎症，这已被证明导致认知能力下降。

Deletion of APOE has been demonstrated to limit disease in multiple AD models. In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies. Key findings from the study include: NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice.Clearance of the ApoE plaques Normalizes neuroinflammation and restores neuroimmune homeostasis.Improves vasodilation in amyloid laden blood vessels,.

已经证明APOE的缺失限制了多种AD模型中的疾病。在临床前AD动物模型中，NC181已证明与淀粉样蛋白靶向治疗有区别。该研究的主要发现包括：NC181与淀粉样蛋白相关的ApoE4结合，导致淀粉样蛋白清除和预防小鼠淀粉样蛋白沉积。ApoE斑块的清除使神经炎症正常化并恢复神经免疫稳态。改善载有淀粉样蛋白的血管中的血管舒张，。